Atopic Dermatitis
Latest News
AD outcomes improved with lebrikizumab and topical steroids
The percentage of patients who achieved the combined endpoint was more than double for the lebrikizumab plus TCS group vs. the group on TCS alone...
Latest News
AAD unveils updated guidelines for topical AD treatment in adults
Of the 12 recommendations made for adults with AD, the work group ranked 7 as “strong” based on the evidence reviewed, and the rest as “...
Latest News
Cochrane Review bolsters case that emollients don’t prevent AD
But that message is being diluted by a stream of contradictory conclusions from poor-quality systematic reviews, authors say.
Original Research
Factors Influencing Patient Preferences for Phototherapy: A Survey Study
This study aimed to determine which form of phototherapy—in-office UVB, at-home UVB, home tanning, salon tanning, and sunbathing—was preferred by...
Latest News
Dupilumab significantly improves markers of AD severity in pediatric patients
Of the 19 severity-associated serum biomarkers measured at baseline, week 4, and week 16, markers related to AD severity and treatment response...
Latest News
Parental atopic dermatitis, asthma linked to risk of AD in offspring
The detailed analysis of AD risk associated with parental atopy in early life “may help to risk stratify infants to optimize early interventions...
Latest News
Pooled safety data analysis of tralokinumab reported
Regarding safety areas of special interest, eye disorders classified as conjunctivitis, keratoconjunctivitis, or keratitis occurred more commonly...
Cosmeceutical Critique
Saururus chinensis
Modern research has produced evidence supporting the use of this plant in the dermatologic realm.
Military Dermatology
Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: Military Considerations
Janus kinase (JAK) inhibitors represent one of the newest and most promising additions to the available treatments of atopic dermatitis (AD).
Latest News
Brepocitinib improves symptoms of mild to moderate AD in phase 2b trial
In addition to AD, brepocitinib is currently being developed as a treatment for dermatomyositis, systemic lupus erythematosus, hidradenitis...
Latest News
Consider gaps in access and knowledge in diagnosis and treatment in skin of color
Expert panel shares best practices for managing common dermatologic conditions in a diverse patient population